GW 4064

CAT: 0804-HY-50108-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-50108-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
GW 4064 is a potent FXR agonist with an EC50 of 65 nM.
CAS Number
[278779-30-9]
UNSPSC
12352005
Hazard Statement
H302, H319, H413
Target
Autophagy; FXR
Type
Reference compound
Related Pathways
Autophagy; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Metabolic Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/GW-4064.html
Purity
99.79
Solubility
DMF : 100 mg/mL (ultrasonic) |DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1=CC=CC(/C=C/C2=CC=C(C=C2Cl)OCC3=C(ON=C3C4=C(Cl)C=CC=C4Cl)C(C)C)=C1)O
Molecular Formula
C28H22Cl3NO4
Molecular Weight
542.84
Precautions
H302, H319, H413
References & Citations
[1]Akwabi-Ameyaw A, et al.Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064. Bioorg Med Chem Lett, 2008, 18 (15), 4339-4343.|[2]Ma Y, et al. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and resistance. Pharm Res. 2013 May;30 (5) :1447-57.|[3]Liu Y, et al. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest. 2003 Dec;112 (11) :1678-87.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products